The direct mode of action of enzalutamide has been shown to translate into clinical responses in patients with mcrpc. Enzalutamide, the first approved ar signalling inhibitor, has a novel mode of action targeting ar signalling at three key stages. Enzalutamide is the first approved ar signalling inhibitor (also described as an ar inhibitor), with a novel mechanism of action, that distinguishes it from both androgen biosynthesis inhibitors (e.g Results from the randomised, phase 3 affirm trial. European society for medical ncology magnitude of clini y ni, dafni u, bogaerts j et l.
OPEN
